Drugs

, Volume 72, Issue 17, pp 2223–2241

Behcet’s Syndrome

Review Article

Abstract

Behcet’s syndrome (BS) is a vasculitis, seen more commonly around the Mediterranean and the Far East, and manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. Its natural history of getting less severe over time, more severe disease in males and lack of specific diagnostic testing separates it from other commonly seen conditions in rheumatology. Most of the serious manifestations respond well to immunosuppression, and these are the mainstays of treatment for BS.

BS is more prevalent in regions along the Silk Road, from the Mediterranean to the Far East. The genetic risk factor most strongly associated with BS is the human leukocyte antigen (HLA)-B51 allele. While genetic factors seem to play a role in the development of certain features of BS, there is general consensus that as yet unidentified environmental stimuli are necessary for initiation of disease. Proposed exogenous triggers include both bacterial and viral infections, which may then lead to dysregulation of the immune system, ultimately leading to the phenotypic expression of disease.

The clinical manifestations of BS are protean in nature. While most patients develop mucocutaneous and genital ulcers along with eye disease, other patients may also present with arthritis, frank vasculitis, thrombophlebitis and CNS disease. Interestingly, the manifestations of this illness vary considerably based on gender and ethnicity.

As the phenotypic expression among patients with BS is quite heterogeneous, pharmacological therapy is variable and dependent upon the severity of the disease as well as organ involvement. Treatment for BS overlaps considerably with therapies for other autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis and the vasculitides. Pharmacological agents utilized for treatment of BS include corticosteroids, colchicine, azathioprine, and tumour necrosis factor (TNF)-α inhibitors, among others. In this article, we review the salient clinical studies for each drug class along with important side effects as well as drug toxicity monitoring.

Management of the patient with BS is complex and oftentimes requires a multidisciplinary approach. We discuss strategies to assess and stratify patients based on clinical manifestations and disease severity. A summary of drug toxicities as they relate to the aforementioned pharmacological agents, as well as guidelines regarding vaccinations in this patient population, are offered. Finally, we conclude with treatment strategies for the common manifestations of BS along with a discussion of the management of thrombotic disease in these patients.

References

  1. 1.
    Zouboulis CC, Keitel W. A historical review of early descriptions of Adamantiades-Behcet’s disease. J Invest Dermatol 2002 Jul; 119(1): 201–5PubMedCrossRefGoogle Scholar
  2. 2.
    Yazici Y, Yurdakul S, Yazici H. Behcet’s syndrome. Curr Rheumatol Rep 2010 Dec; 12(6): 429–35PubMedCrossRefGoogle Scholar
  3. 3.
    Verity DH, Marr JE, Ohno S, et al. Behcet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999 Sep; 54(3): 213–20PubMedCrossRefGoogle Scholar
  4. 4.
    Azizlerli G, Kose AA, Sarica R, et al. Prevalence of Behcet’s disease in Istanbul, Turkey. Int J Dermatol 2003 Oct; 42(10): 803–6PubMedCrossRefGoogle Scholar
  5. 5.
    Cakir N, Dervis E, Benian O, et al. Prevalence of Behcet’s disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol 2004 Jul–Aug; 22 (4 Suppl. 34): 53–5Google Scholar
  6. 6.
    Idil A, Gurler A, Boyvat A, et al. The prevalence of Behcet’s disease above the age of 10 years: the results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey. Ophthalmic Epidemiol 2002 Dec; 9(5): 325–31PubMedCrossRefGoogle Scholar
  7. 7.
    Yurdakul S, Gunaydin I, Tuzun Y, et al. The prevalence of Behcet’s syndrome in a rural area in northern Turkey. J Rheumatol 1988; 15(5): 820–2PubMedGoogle Scholar
  8. 8.
    Kone-Paut I, Darce-Bello M, Shahram F, et al., PED-BD International Expert Committee. Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet’s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford) 2011 Jan; 50(1): 184–8CrossRefGoogle Scholar
  9. 9.
    Krause I, Yankevich A, Fraser A, et al. Prevalence and clinical aspects of Behcet’s disease in the north of Israel. Clin Rheumatol 2007 Apr; 26(4): 555–60PubMedCrossRefGoogle Scholar
  10. 10.
    Papoutsis NG, Abdel-Naser MB, Altenburg A, et al. Prevalence of Adamantiades-Behcet’s disease in Germany and the municipality of Berlin: results of a nationwide survey [published erratum appears in Clin Exp Rheumatol 2007 May–Jun; 25 (3): 507–8]. Clin Exp Rheumatol 2006 Sep–Oct; 24 (5 Suppl. 42): S125PubMedGoogle Scholar
  11. 11.
    Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Behcet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008 Dec; 58(12): 3951–9PubMedCrossRefGoogle Scholar
  12. 12.
    Nakae K, Masaki F, Hashimoto T, et al. Recent epidemiological features of Behcet’s disease in Japan. In: Wechsler B, Godeau P, editors. Behcet’s disease. Amsterdam: Excerpta Medica, 1993: 145–51Google Scholar
  13. 13.
    Yamamoto S, Toyokawa H, Matsubara J, et al. A nationwide survey of Behcet’s disease in Japan. Jpn J Ophthalmol 1974; 18: 282–90Google Scholar
  14. 14.
    Mok CC, Cheung TC, Ho CT, et al. Behcet’s disease in southern Chinese patients. J Rheumatol 2002 Aug; 29(8): 1689–93PubMedGoogle Scholar
  15. 15.
    Ohno S, Aoki K, Sugiura S, et al. HL-A5 and Behcet’s disease [letter]. Lancet 1973 Dec 15; 2(7843): 1383–4CrossRefGoogle Scholar
  16. 16.
    Ohno S, Asanuma T, Sugiura S, et al. HLA-Bw51 and Behcet’s disease. JAMA 1978 Aug 11; 240(6): 529PubMedCrossRefGoogle Scholar
  17. 17.
    Moore SB, O’Duffy JD. Lack of association between Behcet’s disease and major histocompatibility complex class II antigens in an ethnically diverse North American Caucasoid patient group. J Rheumatol 1986 Aug; 13(4): 771–3PubMedGoogle Scholar
  18. 18.
    Gul A. Behcet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 2001 Sep–Oct; 19 (5 Suppl. 24): 6–12Google Scholar
  19. 19.
    Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL-6 and interferongamma by T cells from patients with Behcet’s disease. Cell Immunol 1992 Apr; 140(2): 410–9PubMedCrossRefGoogle Scholar
  20. 20.
    Kaneko F, Oyama N, Yanagihori H, et al. The role of streptococcal hypersensitivity in the pathogenesis of Behcet’s disease. Eur J Dermatol 2008 Sep–Oct; 18(5): 489–98PubMedGoogle Scholar
  21. 21.
    Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet’s disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol 2006 Nov–Dec; 35(6): 472–5PubMedCrossRefGoogle Scholar
  22. 22.
    Frassanito MA, Dammacco R, Cafforio P, et al. Th1 polarization of the immune response in Behcet’s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999 Sep; 42(9): 1967–74PubMedCrossRefGoogle Scholar
  23. 23.
    Raziuddin S, al-Dalaan A, Bahabri S, et al. Divergent cytokine production profile in Behcet’s disease: altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998 Feb; 25(2): 329–33PubMedGoogle Scholar
  24. 24.
    Sakane T, Takeno M, Suzuki N, et al. Behcet’s disease. N Eng J Med 1999 Oct 21; 341(17): 1284–91CrossRefGoogle Scholar
  25. 25.
    Sahin S, Akoglu T, Direskeneli H, et al. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behcet’s disease. Ann Rheum Dis 1996 Feb; 55(2): 128–33PubMedCrossRefGoogle Scholar
  26. 26.
    Musabak U, Pay S, Erdem H, et al. Serum interleukin-18 levels in patients with Behcet’s disease: is its expression associated with disease activity or clinical presentations? Rheumatol Int 2006 Apr; 26(6): 545–50PubMedCrossRefGoogle Scholar
  27. 27.
    Pay S, Musabak U, Simsek I, et al. Expression of CXCR-1 and CXCR-2 chemokine receptors on synovial neutrophils in inflammatory arthritides: does persistent or increasing expression of CXCR-2 contribute to the chronic inflammation or erosive changes? Joint Bone Spine 2006 Dec; 73(6): 691–6PubMedCrossRefGoogle Scholar
  28. 28.
    Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behcet’s disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003 Jul–Aug; 21 (4 Suppl. 30): S35–7PubMedGoogle Scholar
  29. 29.
    Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet’s disease. Yonsei Med J 2007 Aug 31; 48(4): 573–85PubMedCrossRefGoogle Scholar
  30. 30.
    Ergun T, Gurbuz O, Dogusoy G, et al. Histopathologic features of the spontaneous pustular lesions of Behcet’s syndrome. Int J Dermatol 1998 Mar; 37(3): 194–6PubMedCrossRefGoogle Scholar
  31. 31.
    Alpsoy E, Donmez L, Onder M, et al. Clinical features and natural course of Behçet’s disease in 661 cases: a multicentre study. Br J Dermatol 2007 Nov; 157(5): 901–6PubMedCrossRefGoogle Scholar
  32. 32.
    Yazici Y, Moses N. Clinical manifestations and ethnic background of patients with Behcet’s Syndrome in a US cohort [abstract]. Arthritis Rheum 2007; 56: S: 502Google Scholar
  33. 33.
    Yazici H, Chamberlain MA, Tuzun Y, et al. A comparative study of the pathergy reaction among Turkish and British patients with Behcet’s disease. Ann Rheum Dis 1984 Feb; 43(1): 74–5PubMedCrossRefGoogle Scholar
  34. 34.
    Davatchi F, Chams-Davatchi C, Ghodsi Z, et al. Diagnostic value of pathergy test in Behcet’s disease according to the change of incidence over the time. Clin Rheumatol 2011 Sep; 30(9): 1151–5PubMedCrossRefGoogle Scholar
  35. 35.
    Davatchi F, Sadeghi Abdollahi B, Chams-Davatchi C, et al. Impact of the positive pathergy test on the performance of classification/diagnosis criteria for Behcet’s disease. Mod Rheumatol. Epub 2012 Apr 4Google Scholar
  36. 36.
    Fresko I, Yazici H, Bayramiçli M, et al. Effect of surgical cleaning of the skin on the pathergy phenomenon in Behçet’s syndrome. Ann Rheum Dis 1993 Aug; 52(8): 619–20PubMedCrossRefGoogle Scholar
  37. 37.
    Dilsen N, Konice M, Aral O, et al. Comparative study of the skin pathergy test with blunt and sharp needles in Behcet’s disease: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis 1993 Nov; 52(11): 823–5PubMedCrossRefGoogle Scholar
  38. 38.
    Hatemi G, Yazici H. Behçet’s syndrome and microorganisms. Best Pract Res Clin Rheumatol 2011 Jun; 25(3): 389–406PubMedCrossRefGoogle Scholar
  39. 39.
    Tugal-Tutkun I, Opal S, Altan-Yaylacioglu R, et al. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 2004 Sep; 138(3): 373–80PubMedCrossRefGoogle Scholar
  40. 40.
    Maghraoui AE, Tabache F, Bezza A, et al. A controlled study of sacroiliitis in Behcet’s disease. Clin Rheumatol 2001; 20(3): 189–91PubMedCrossRefGoogle Scholar
  41. 41.
    Yurdakul S, Yazici H, Tuzun Y, et al. The arthritis of Behcet’s disease: a prospective study. Ann Rheum Dis 1983 Oct; 42(5): 505–15PubMedCrossRefGoogle Scholar
  42. 42.
    Diri E, Mat C, Hamuryudan V, et al. Papulopustular skin lesions are seen more frequently in patients with Behcet’s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis 2001 Nov; 60(11): 1074–6PubMedCrossRefGoogle Scholar
  43. 43.
    Hatemi G, Fresko I, Tascilar K, et al. Increased enthesopathy among Behcet’s syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum 2008 May; 58(5): 1539–45PubMedCrossRefGoogle Scholar
  44. 44.
    Karaca M, Hatemi G, Sut N, et al. The papulopustular lesion/arthritis cluster of Behcet’s syndrome also clusters in families. Rheumatology (Oxford) 2012 Jun; 51(6): 1053–60CrossRefGoogle Scholar
  45. 45.
    Tohme A, Aoun N, El-Rassi B, et al. Vascular manifestations of Behcet’s disease: eighteen cases among 140 patients. Joint Bone Spine 2003 Sep; 70(5): 384–9PubMedCrossRefGoogle Scholar
  46. 46.
    Saadoun D, Asli B, Wechsler B, et al. Long-term outcome of arterial lesions in Behcet disease: a series of 101 patients. Medicine (Baltimore) 2012 Jan; 91(1): 18–24CrossRefGoogle Scholar
  47. 47.
    Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine (Baltimore) 2012 Jan; 91(1): 35–48CrossRefGoogle Scholar
  48. 48.
    Geri G, Wechsler B, Thi Huong du L, et al. Spectrum of cardiac lesions in Behcet disease: a series of 52 patients and review of the literature. Medicine (Baltimore) 2012 Jan; 91(1): 25–34CrossRefGoogle Scholar
  49. 49.
    Gokcay F, Celebisoy N, Gokcay A, et al. Neurological symptoms and signs in Behcet disease: a Western Turkey experience. Neurologist 2011 May; 17(3): 147–50PubMedCrossRefGoogle Scholar
  50. 50.
    Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet’s disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 1999 Nov; 122 (Pt 11): 2171–82PubMedCrossRefGoogle Scholar
  51. 51.
    Aykutlu E, Baykan B, Akman-Demir G, et al. Headache in Behcet’s disease. Cephalalgia 2006 Feb; 26(2): 180–6PubMedCrossRefGoogle Scholar
  52. 52.
    Kulahli I, Balci K, Koseoglu E, et al. Audio-vestibular disturbances in Behcet’s patients: report of 62 cases. Hear Res 2005 May; 203(1–2): 28–31PubMedCrossRefGoogle Scholar
  53. 53.
    Jankowski J, Crombie I, Jankowski R. Behcet’s syndrome in Scotland. Postgrad Med J 1992 Jul; 68(801): 566–70PubMedCrossRefGoogle Scholar
  54. 54.
    Shimizu T, Ehrlich GE, Inaba G, et al. Behcet disease (Behcet syndrome). Semin Arthritis Rheum 1979 May; 8(4): 223–60PubMedCrossRefGoogle Scholar
  55. 55.
    Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet’s disease. Int J Dermatol 2003 May; 42(5): 346–51PubMedCrossRefGoogle Scholar
  56. 56.
    Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Behcet’s disease. Inflamm Bowel Dis 2001 Aug; 7(3): 243–9PubMedCrossRefGoogle Scholar
  57. 57.
    Wang WB, Zhao YP, Cong L, et al. Clinical characters of gastrointestinal lesions in intestinal Behcet’s disease. Chin Med Sci J 2011 Sep; 26(3): 168–71PubMedCrossRefGoogle Scholar
  58. 58.
    Koklu S, Yuksel O, Onur I, et al. Ileocolonic involvement in Behcet’s disease: endoscopic and histological evaluation. Digestion 2010; 81(4): 214–7PubMedCrossRefGoogle Scholar
  59. 59.
    Akpolat T, Dilek M, Aksu K, et al. Renal Behcet’s disease: an update. Semin Arthritis Rheum 2008 Dec; 38(3): 241–8PubMedCrossRefGoogle Scholar
  60. 60.
    International Study Group for Behcet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet 1990 May 5; 335(8697): 1078–80Google Scholar
  61. 61.
    Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet’s syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003 Jan; 82(1): 60–76CrossRefGoogle Scholar
  62. 62.
    Saadoun D, Wechsler B, Desseaux K, et al. Mortality in Behçet’s disease. Arthritis Rheum 2010 Sep; 62(9): 2806–12PubMedCrossRefGoogle Scholar
  63. 63.
    Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary arterial aneurysms in Behcet’s syndrome: a report of 24 cases. Br J Rheumatol 1994 Jan; 33(1): 48–51PubMedCrossRefGoogle Scholar
  64. 64.
    Bayraktar Y, Balkanci F, Bayraktar M, et al. Budd-Chiari syndrome: a common complication of Behcet’s disease. Am J Gastroenterol 1997 May; 92(5): 858–62PubMedGoogle Scholar
  65. 65.
    Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behcet syndrome. Am J Med 2004 Dec 1; 117(11): 867–70PubMedCrossRefGoogle Scholar
  66. 66.
    Siva A, Kantarci OH, Saip S, et al. Behcet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 2001 Feb; 248(2): 95–103PubMedCrossRefGoogle Scholar
  67. 67.
    Seyahi E, Yazici H. Prognosis in Behcet’s Syndrome. In: Yazici Y, Yazici H, editors. Behcet’s syndrome. New York: Springer, 2010: 285–95CrossRefGoogle Scholar
  68. 68.
    Chung YM, Lin YC, Tsai CC, et al. Behcet’s disease with uveitis in Taiwan. J Chin Med Assoc 2008 Oct; 71(10): 509–16PubMedCrossRefGoogle Scholar
  69. 69.
    Cho YJ, Kim WK, Lee JH, et al. Visual prognosis and risk factors for Korean patients with Behcet uveitis. Ophthalmologica 2008; 222(5): 344–50PubMedCrossRefGoogle Scholar
  70. 70.
    Melikoglu M, Ugurlu S, Tascilar K, et al. Large vessel involvement in Behcet’s syndrome: a retrospective survey [abstract]. Ann Rheum Dis 2008; 67 Suppl. II: 67Google Scholar
  71. 71.
    Diri E, Espinoza LR. Neuro-Behcet’s syndrome: differential diagnosis and management. Curr Rheumatol Rep 2006 Aug; 8(4): 317–22PubMedCrossRefGoogle Scholar
  72. 72.
    Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behcet’s syndrome. Rheumatology (Oxford) 2006 Mar; 45(3): 348–52CrossRefGoogle Scholar
  73. 73.
    Aktulga E, Altac M, Muftuoglu A, et al. A double-blind study of colchicine in Behcet’s disease. Haematologica 1980 Jun; 65(3): 399–402PubMedGoogle Scholar
  74. 74.
    Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet’s syndrome. Arthritis Rheum 2001 Nov; 44(11): 2686–92PubMedCrossRefGoogle Scholar
  75. 75.
    Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behcet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009; 19(5): 542–9PubMedCrossRefGoogle Scholar
  76. 76.
    Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet’s syndrome. N Eng J Med 1990 Feb 1; 322(5): 281–5CrossRefGoogle Scholar
  77. 77.
    Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum 1997 Apr; 40(4): 769–74PubMedCrossRefGoogle Scholar
  78. 78.
    Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996 Sep; 80 (3 Pt 2): S: 40–5CrossRefGoogle Scholar
  79. 79.
    Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial. Br J Ophthalmol 1992 Apr; 76(4): 241–3PubMedCrossRefGoogle Scholar
  80. 80.
    Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1989 May 20; 1(8647): 1093–6PubMedCrossRefGoogle Scholar
  81. 81.
    Robertson M, Liversidge J, Forrester JV, et al. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2003 Jul; 44(7): 3034–41PubMedCrossRefGoogle Scholar
  82. 82.
    Greiner K, Murphy CC, Willermain F, et al. Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci 2004 Jan; 45(1): 170–6PubMedCrossRefGoogle Scholar
  83. 83.
    Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci 2008 Jul; 49(7): 3058–64PubMedCrossRefGoogle Scholar
  84. 84.
    Sugita S, Kawazoe Y, Imai A, et al. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet’s disease. Arthritis Res Ther 2012 May 1; 14(3): R99PubMedCrossRefGoogle Scholar
  85. 85.
    Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2004 Mar 2; 140(5): 404–6PubMedGoogle Scholar
  86. 86.
    Cantini F, Niccoli L, Nannini C, et al. Efficacy of infliximab in refractory Behcet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics 2012; 6(5): 5–12PubMedGoogle Scholar
  87. 87.
    Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease. Mod Rheumatol 2011 Apr; 21(2): 184–91PubMedCrossRefGoogle Scholar
  88. 88.
    Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol 2005 Jan; 32(1): 98–105PubMedGoogle Scholar
  89. 89.
    Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Behcet’s disease: review of the literature. Semin Arthritis Rheum 2004 Apr; 33(5): 320–35PubMedCrossRefGoogle Scholar
  90. 90.
    Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003 Apr; 87(4): 423–31PubMedCrossRefGoogle Scholar
  91. 91.
    Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002 Apr; 138(4): 467–71PubMedCrossRefGoogle Scholar
  92. 92.
    Hatemi G, Silman A, Bang D, et al., (EULAR Expert Committee). EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008 Dec; 67(12): 1656–62PubMedCrossRefGoogle Scholar
  93. 93.
    Ait Ben Haddou EH, Imounan F, Regragui W, et al. Neurological manifestations of Behçet’s disease: evaluation of 40 patients treated by cyclophosphamide. Rev Neurol (Paris) 2012 Apr; 168(4): 344–9CrossRefGoogle Scholar
  94. 94.
    University of Leeds. Psychometric laboratory for health sciences [online]. Available from URL: http://www.leeds.ac.uk/medicine/rehabmed/psychometric/Scales1.htm [Accessed 2012 Nov 13]
  95. 95.
    Lawton G, Bhakta BB, Chamberlain MA, et al. The Behcet’s disease activity index. Rheumatology (Oxford) 2004 Jan; 43(1): 73–894CrossRefGoogle Scholar
  96. 96.
    Mumcu G, Yazici Y, Chamberlain A. Disease assessment in Behcet’s disease. In: Yazici Y, Yazici Y, editors. Behcet’s syndrome. New York: Springer, 2010: 299–315CrossRefGoogle Scholar
  97. 97.
    Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet’s syndrome. Int J Dermatol 2003 Nov; 42(11): 870–5PubMedCrossRefGoogle Scholar
  98. 98.
    Nanke Y, Kotake S, Goto M, et al. Decreased percentages of regulatory T cells in peripheral blood of patients with Behcet’s disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol 2008; 18(4): 354–8PubMedCrossRefGoogle Scholar
  99. 99.
    Pay S, Abbasov T, Erdem H, et al. Serum MMP-2 and MMP-9 in patients with Behcet’s disease: do their higher levels correlate to vasculo-Behcet’s disease associated with aneurysm formation? Clin Exp Rheumatol 2007 Jul–Aug; 25 (4 Suppl. 45): 70–5Google Scholar
  100. 100.
    Bicer A, Tursen U, Kaya TI, et al. Bone mineral density in patients with Behcet’s disease. Rheumatol Int 2004 Nov; 24(6): 355–8PubMedCrossRefGoogle Scholar
  101. 101.
    Tekin NS, Ozdolap S, Sarikaya S, et al. Bone mineral density and bone turnover markers of patients with Behcet’s disease. J Eur Acad Dermatol Venereol 2007 Jan; 21(1): 25–9PubMedCrossRefGoogle Scholar
  102. 102.
    Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with combined use of simvastatin and colchicine. J Clin Rheumatol 2007 Oct; 13(5): 266–8PubMedCrossRefGoogle Scholar
  103. 103.
    Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment: a pharmacogenomic test whose time has come. J Clin Pathol 2010 Apr; 63(4): 288–95PubMedCrossRefGoogle Scholar
  104. 104.
    Akman-Demir G, Ayranci O, Kurtuncu M, et al. Cyclosporine for Behçet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 2008 Jul–Aug; 26 (4 Suppl. 50): S84–90PubMedGoogle Scholar
  105. 105.
    Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999 Mar; 106(3): 586–9PubMedCrossRefGoogle Scholar
  106. 106.
    Kötter I, Günaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A (CSA) than under other medications: results of a retrospective analysis of 117 cases. Clin Rheumatol 2006 Jul; 25(4): 482–6PubMedCrossRefGoogle Scholar
  107. 107.
    Perez-Alvarez R, Diaz-Lagarez C, Garcia-Hernandez F, et al., BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 case. Medicine (Baltimore) 2011 Nov; 90(6): 359–71CrossRefGoogle Scholar
  108. 108.
    Hayden, Frederick. Antimicrobial agents: antiviral agents. In: Hardman JG, Limbird LE, Gillman AG, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill, 2001: 1313–47Google Scholar
  109. 109.
    Hamuryudan V, Kotter I. Medical management of Behcet’s syndrome. In: Yazici Y, Yazici H, editors. Behcet’s syndrome. New York: Springer, 2010: 317–38CrossRefGoogle Scholar
  110. 110.
    Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 2009 Oct; 68(10): 1528–34PubMedCrossRefGoogle Scholar
  111. 111.
    Erkek E, Ayaslioglu E, Erkek AB, et al. Response to vaccination against hepatitis B in patients with Behcet’s disease. J Gastroenterol Hepatol 2005 Oct; 20(10): 1508–11PubMedCrossRefGoogle Scholar
  112. 112.
    Saad CG, Borba EF, Aikawa NE, et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic disease. Ann Rheum Dis 2011 Jun; 70(6): 1068–73PubMedCrossRefGoogle Scholar
  113. 113.
    National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published erratum appears in MMWR Recomm Rep 2011 Jul 29; 60: 993]. MMWR Recomm Rep 2011 Jan 28; 60(2): 1–64Google Scholar
  114. 114.
    Sarica-Kucukoglu R, Akdag-Kose A, Kayabali M, et al. Vascular involvement in Behcet’s disease: a retrospective analysis of 2319 cases. Int J Dermatol 2006 Aug; 45(8): 919–21PubMedCrossRefGoogle Scholar
  115. 115.
    Kobayashi M, Ito M, Nagakawa A, et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behcet disease. Histopathology 2000 Apr; 36(4): 362–71PubMedCrossRefGoogle Scholar
  116. 116.
    Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behcet’s disease. Am J Ophthalmol 2004 May; 137(5): 850–7PubMedCrossRefGoogle Scholar
  117. 117.
    Sari RA, Kiziltunc A, Taysi S, et al. Levels of soluble E-selectin in patients with active Behcet’s disease. Clin Rheumatol 2005 Feb; 24(1): 55–9PubMedCrossRefGoogle Scholar
  118. 118.
    Espinoza G, Font J, Tassies D, et al. Vascular involvement in Behcet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002 Jan; 112(1): 37–43CrossRefGoogle Scholar
  119. 119.
    Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet’s disease. Ann Rheum Dis 2004 Nov; 63(11): 1445–9PubMedCrossRefGoogle Scholar
  120. 120.
    Mader R, Ziv M, Adawi M, et al. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet’s disease. J Rheumatol 1999 Nov; 26(11): 2404–8PubMedGoogle Scholar
  121. 121.
    Ahn JK, Lee YS, Jeon CH, et al. Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008 Feb; 27(2): 201–5PubMedCrossRefGoogle Scholar
  122. 122.
    Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Behçet’s disease. Arthritis Rheum 2012 Aug; 64(8): 2753–60PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Division of RheumatologyDuke University Medical CenterDurhamUSA
  2. 2.NYU Hospital for Joint DiseasesNew YorkUSA
  3. 3.Center for Musculoskeletal CareNYU Hospital for Joint DiseasesNew YorkUSA

Personalised recommendations